Latest News and Press Releases

To Nasdaq Copenhagen 8 January 2026 FIXING OF COUPON RATES        Fixing of coupon rates effective from 12 January 2026 Effective from 12 January 2026, the coupon rates of floating-rate bonds...

DENVER, Jan. 08, 2026 (GLOBE NEWSWIRE) -- The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a leader in the Nutritional Snacking Category, today reported...

Miami, FL, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ONAR Holding Corporation (OTCQB: ONAR) (“ONAR” or the “Company”), an AI-powered marketing platform that acquires and scales specialist agencies, today...

Grace E. Colón, Ph.D., Appointed Chair of the Board of Directors John Glasspool Appointed Board Director Lekhan Shivashankar Appointed Chief of Staff New Additions Strengthen Aronora as it Advances...

LONDON and MILAN, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced...

Transpire Bio CEO Dr. Xian-Ming Zeng will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026

SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...

Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD...

Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine...

First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026  Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved...